Cancer

Addition of elotuzumab ups PFS in refractory multiple myeloma

(HealthDay)—For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival (PFS) is longer in those receiving the immunostimulatory monoclonal antibody ...

Cancer

A rare disease inspires a new way to attack cancer

Some of the most promising new treatments for blood cancers, drugs called proteasome inhibitors, have a problem: For reasons that researchers are still working to fully understand, cancer cells can build up a resistance to ...

Diseases, Conditions, Syndromes

New compound targets TB bacterium's defense against the immune system

Part of the reason tuberculosis-causing bacteria are so good at colonizing the human body is that they have defenses against the body's immune system. A research team led by a Brown University chemist has developed a new ...

page 1 from 4